BCLI Brainstorm Cell Therapeutics, Inc.: Earnings per share for the last 12 months
The specifics of manual cell modification on the Nuown platform limit production scales, which is offset by the high cost of the drugs. The annual percentage change in earnings per share (TTM) visualizes this financial dynamic, where 37.70 shows the level of this metric. Brainstorm Cell (BCLI) is diversifying risks by developing treatments for sclerosis and ALS, seeking accelerated FDA approval for its developments.
BCLI (Brainstorm Cell Therapeutics, Inc.): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- book capitalization indicators:
- debt and liquidity data:
Debt to Capital Brainstorm Cell|BCLI - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital BrainStorm Cell Therapeutics Inc.|BCLI - Company Debts|Debt to Book Value Brainstorm Cell Therapeutics, Inc.|BCLI - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings BrainStorm Cell Therapeutics|Quick Liquidity Indicator brainstorm-cell.com
- business earnings and investment ratios data:
BCLI - Net Profit|Expected Net Profit Brainstorm Cell|BCLI - Price to Earnings Ratio|Future Price to Earnings Brainstorm Cell Therapeutics Inc.|BCLI - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Brainstorm Cell Therapeutics, Inc.|BCLI - Operating profit EBITDA|Earnings per share for the last twelve months BrainStorm Cell Therapeutics|BCLI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months brainstorm-cell.com|BCLI - Earnings per share growth in current year|Net earnings per share growth forecast for next year Brainstorm Cell
Initial company analysis:Brainstorm Cell
The scale of the Brainstorm Cell (BCLI) biotech business is reflected in the annual growth trend of net income per share TTM. This indicator captures the rolling annual expansion rate of profit, adjusted for one-off factors. The calculation measures the efficiency of intellectual property monetization amid tight Fed policy. For a company with the closed patent perimeter of NurOwn, this metric confirms the commercial viability of therapy protocols. Steady growth in this indicator signals a transition from the R&D stage to capitalization.
Direct competitors
Net earnings per share for the last four quarters biogen.com BIIB|Neurocrine Biosciences, Inc. (NBIX) - Earnings per share for the last twelve months|Earnings per share for the last 12 months RGC|Earnings per share for the last twelve months Axsome Therapeutics Inc|ACADIA Corp (ACAD) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months XENE (Xenon Pharmaceuticals)|Earnings per share for the last four quarters VKTX|Earnings per share for the last twelve months Supernus SUPN|Catalyst Pharma (CPRX) - Net earnings per one share for the last twelve months|DNLI - Earnings per share for the last twelve months|Earnings per share for the trailing year HRMY (Harmony Corp)|Biohaven Ltd. (BHVN) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months amylyx.com|Net earnings per share for the last 12 months TRVI|PRAX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) AVXL|Net earnings per share for the last 12 months CeriBell EEG CBLL|Net earnings per share (EPS TTM) PRTA (Prothena Corporation)|Alector Inc. (ALEC) - Net earnings per one share for the last twelve months|ANNX - Earnings per share for the last twelve months|OMER: Earnings per share for the last twelve months|Neurogene Corp (NGNE) - Earnings per share for the last twelve months|ACIU (AC Immune Inc) - Earnings per share for the last twelve months|VYGR (Voyager Therapeutics) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months NMRA|Net earnings per share (EPS TTM) SCLX|Net earnings per share for the last 12 months Tevogen Bio Holdings Inc. TVGN|Earnings per share for the last twelve months Alpha Cognition Inc. ACOG|cogrx.com - Earnings per share for the last twelve months|Inhibikase Therapeutics - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters cassavasciences.com SAVA|assertiotx.com (ASRT) - Earnings per share for the last twelve months|Earnings per share for the last 12 months COYA|VTGN (VistaGen Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Ovid Rx OVID|Net earnings per share for the last 12 months ABOS (Acumen Pharmaceuticals)|Net earnings per share (EPS TTM) cervomed.com (CRVO)|Earnings per share for the last twelve months Alterity Therapeutics Limited ATHE|Earnings per share for the trailing year CLNN|PEPG - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months jupiterneurosciences.com|RLMD: Net earnings per share (EPS TTM)|ANVS (annovisbio.com) - Earnings per share for the last twelve months|Earnings per share for the last twelve months Grace Therapeutics Inc|AIFF: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KLTO|Net earnings per share (EPS TTM) neurosense-tx.com (NRSN)|Net earnings per share (EPS TTM) RVPH (Reviva Pharmaceuticals)|Net earnings per share for the last four quarters MetaVia Inc. (MTVA)|NRXS - Earnings per share for the last twelve months|HSDT (Helius Medical) - Earnings per share for the last 12 months|passagebio.com (PASG) - Earnings per share for the last twelve months|NEUP - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months NERV|ATHA (athira.com) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Addex Therapeutics Ltd (ADXN)|ALZN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Cyclerion Therapeutics, Inc. CYCN|Earnings per share for the trailing year PTIX|KTTA - Earnings per share for the last twelve months|Cortigent, Inc. (CRGT) - Net earnings per share for the last 12 months|ATXI (Avenue Therapeutics, Inc.) - Net earnings per share for the last 12 months|Cara Therapeutics Inc. - Earnings per share for the trailing year|CHRO (Chromocell Therapeutics Corporation) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Eliem (ELYM)|Net earnings per share (EPS TTM) ITCI|LBPH - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Marinus Pharmaceuticals, Inc. MRNS|NKGen Biotech Inc - Earnings per share for the last twelve months|NRBO - Earnings per share for the last twelve months|SAGE: Earnings per share for the last twelve months|SNPX: Net earnings per share (EPS TTM)|TRVN (trevena.com) - Earnings per share for the last twelve months|VIGL (Vigil Neuroscience Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Anew Medical Inc. (WENA)|Earnings per share for the last twelve months Cerevel (CERE)
